SB
Stephen Bloch
Chief Executive Officer at EvolveImmune Therapeutics
Westport, Connecticut
Overview
Stephen Bloch is the CEO of EvolveImmune Therapeutics, with a background in venture capital and entrepreneurship. He has held leadership positions in various healthcare companies and has successfully invested in several notable companies such as Truveris and Liquidia Technologies.
Bloch's career highlights include serving as the CEO of Allyx Therapeutics, Inc., and as a General Partner at Canaan Partners, demonstrating his expertise in leading companies and making strategic investments in the healthcare industry.
Work Experience
Chief Executive Officer
2019 - Current
EvolveImmune Therapeutics develops a modular biotherapeutics platform specialized in immuno-oncology.
Raised $74,948,366.00 from Yonjin Venture, Pfizer, Takeda Ventures, Elm Street Ventures and Solasta Ventures.
Chief Executive Officer
2019
General Partner
2002
Canaan is an early-stage venture capital firm that invests in visionaries with transformative ideas.
Chairman Of The Board
2018
Chief Executive Officer
1995 - 2002
consultant
1994 - 1995
Education
AB
1980 - 1984
Doctor of Medicine (MD)
1984 - 1989
Master of Arts (MA)
1987 - 1988